Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.

andrew schmidt,Angelyn Anton,Shirley Wong,Arun Azad,Edmond M. Kwan,Lavinia Spain,Javier Torres,Arunbalaji Muthusamy,Phillip Parente,Francis Parnis,Jeffrey C. Goh,Anthony M. Joshua,David William Pook,Peter Gibbs,Ben Tran,Andrew J. Weickhardt

Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.

2020

andrew schmidt
Angelyn Anton
Shirley Wong
Arun Azad
Edmond M. Kwan
Lavinia Spain
Javier Torres
Arunbalaji Muthusamy
Phillip Parente
Francis Parnis
Jeffrey C. Goh
Anthony M. Joshua
David William Pook
Peter Gibbs
Ben Tran
Andrew J. Weickhardt

78Background: There is no prospective data to guide optimal selection of treatment for first line (1L) mCRPC after D and androgen deprivation therapy (ADT) is given in the hormone sensitive setting...

Keywords:

Pathology
Disease
Oncology
Castrate-resistant prostate cancer
Internal medicine
Androgen deprivation therapy
Docetaxel
Hormone-sensitive
Medicine
first line
prospective data
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations